Eosinophilic otitis media treated with anti-ige monoclonal antibodies and a bone conduction implant

16Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

Abstract

Eosinophilic otitis media (EOM) are intractable otitis media characterized by highly viscous secretions containing eosinophils in the middle ear. They are resistant to conventional medication and surgery. This condition occurs primarily in patients with bronchial asthma or allergic rhinitis and is often complicated by rhinosinusitis. Systemic and topical steroid therapies are effective treatments. However, long-term steroid therapy is often limited by a high risk of serious adverse effects. The use of topical steroids and otorrhea are bothersome when wearing hearing aids. Here, we report a case of intractable otitis media due to EOM. Otorrhea was controlled with topical steroids. Bone conduction hearing was stable for an extended period with anti-IgE monoclonal antibodies (omalizumab). An implantable bone conduction hearing aid was used for rehabilitation of conductive hearing loss.

Cite

CITATION STYLE

APA

Han, Y. E., Kang, Y. S., Cho, Y., & Park, M. K. (2018). Eosinophilic otitis media treated with anti-ige monoclonal antibodies and a bone conduction implant. Journal of International Advanced Otology, 14(1), 144–147. https://doi.org/10.5152/iao.2018.4517

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free